Xevinapant combined with pembrolizumab in patients with advanced, pretreated colorectal and pancreatic cancer: results of the phase 1b/2 CATRIPCA trial.
Fiche publication
Date publication
mars 2024
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane
Tous les auteurs :
Voisin A, Terret C, Schiffler C, Bidaux AS, Vanacker H, Perrin-Niquet M, Barbery M, Vinceneux A, Eberst L, Stephan P, Garin G, Spaggiari D, Pérol D, Grinberg-Bleyer Y, Cassier PA
Lien Pubmed
Résumé
Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers (ICB) by modulating the NF-KB pathway in immune cells.
Référence
Clin Cancer Res. 2024 03 19;: